Form 4: Guardian Pharmacy Services CEO Sells Over 885,000 Shares in Public Offering

Fred Burke, President and CEO of Guardian Pharmacy Services, Inc., has reported the sale of 885,807 shares of Class A Common Stock for approximately $17.85 million, as part of a pre-arranged underwriting agreement.

Summary

• Fred Burke, President and Chief Executive Officer of Guardian Pharmacy Services, Inc. (GRDN), reported transactions on May 27, 2025, and May 28, 2025.
• On May 27, 2025, Mr. Burke disposed of 747,102 shares of Class A Common Stock at a price of $20.16 per share.
• On May 28, 2025, an additional 138,705 shares of Class A Common Stock were disposed of at the same price of $20.16 per share.
• The total number of shares sold across both transactions is 885,807.
• The total value of the shares sold is approximately $17,850,687.12 (885,807 shares * $20.16/share).
• Following these transactions, Mr. Burke beneficially owns 413,019 shares of Class A Common Stock directly.
• These sales were conducted pursuant to an Underwriting Agreement dated May 22, 2025, involving the Issuer, selling stockholders, and Raymond James & Associates, Inc. as representative of the underwriters.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly cautious. While a large insider sale can be viewed negatively, the fact that it was part of a pre-arranged underwriting agreement suggests a planned event rather than an immediate reaction to negative company prospects. It's a significant reduction in the CEO's direct ownership.

Negatives

• A significant sale of shares by a key executive, such as the President and CEO, can sometimes be perceived negatively by investors as it may suggest a lack of confidence, although in this case it was part of a pre-arranged underwriting agreement.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends, but large insider sales can sometimes influence market perception within the healthcare services sector, particularly for pharmacy services companies.

Stakeholder Impact

• Shareholders: The sale of a significant number of shares by the CEO could lead to questions about management's long-term commitment or confidence, potentially impacting investor sentiment and share price, although the pre-arranged nature mitigates some concerns.

Key Dates

Keywords

Form 4, Insider Trading, Stock Sale, Beneficial Ownership, Guardian Pharmacy Services, GRDN, Fred Burke, CEO, Underwriting Agreement, Secondary Offering